Christian T. Ruff, MD, MPH is currently an Associate Physician in the Cardiovascular Division at Brigham and Women’s Hospital in Boston, MA and an Assistant Professor of Medicine at Harvard Medical School. He was a lead co-investigator for the ENGAGE AF-TIMI 48 study evaluating the investigational, oral, once-daily, factor Xa inhibitor edoxaban for the prevention of stroke or systemic embolic events in patients with non-valvular atrial fibrillation.

Dr. Ruff graduated from Harvard University with a degree in Neurobiology and earned his medical degree at the Johns Hopkins University School of Medicine and his Masters of Public Health at the Harvard School of Public Health. Dr. Ruff completed his internal medicine residency and cardiovascular medicine fellowship at the Brigham and Women’s Hospital.

Dr. Ruff is an investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group and serves as the Assistant Director of the Clinical Events Committee. He has led a broad array of projects, ranging from small studies of biomarkers and genetic variants to large clinical trials. Dr. Ruff has specific expertise in risk stratification in atrial fibrillation and implementation of novel antithrombotic therapy for stroke prevention and has been selected to serve as the Chairman for the Stroke Prevention in Atrial Fibrillation Consensus Initiative for NATF. Dr. Ruff has authored more than 40 scholarly articles, editorials, reviews, and book chapters and has given dozens of lectures nationally and internationally. His clinical research has been published in several peer-reviewed journals, including The New England Journal of Medicine, Lancet, The Journal of the American Medical Association, American Journal of Medicine, Circulation and Nature Reviews Cardiology.